RU2014147869A - The use of alginate salt as a lipid sorbent, pharmaceutical composition and drug for the treatment of obesity - Google Patents
The use of alginate salt as a lipid sorbent, pharmaceutical composition and drug for the treatment of obesity Download PDFInfo
- Publication number
- RU2014147869A RU2014147869A RU2014147869A RU2014147869A RU2014147869A RU 2014147869 A RU2014147869 A RU 2014147869A RU 2014147869 A RU2014147869 A RU 2014147869A RU 2014147869 A RU2014147869 A RU 2014147869A RU 2014147869 A RU2014147869 A RU 2014147869A
- Authority
- RU
- Russia
- Prior art keywords
- alginate
- pharmaceutical composition
- salts
- granules
- sorbent
- Prior art date
Links
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract 13
- 150000002632 lipids Chemical class 0.000 title claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 7
- 239000002594 sorbent Substances 0.000 title claims abstract 5
- 208000008589 Obesity Diseases 0.000 title claims abstract 3
- 239000003814 drug Substances 0.000 title claims abstract 3
- 235000020824 obesity Nutrition 0.000 title claims abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 239000008187 granular material Substances 0.000 claims abstract 8
- 238000001879 gelation Methods 0.000 claims abstract 4
- 230000001057 ionotropic effect Effects 0.000 claims abstract 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000010521 absorption reaction Methods 0.000 claims abstract 2
- 229940072056 alginate Drugs 0.000 claims abstract 2
- 235000010443 alginic acid Nutrition 0.000 claims abstract 2
- 229920000615 alginic acid Polymers 0.000 claims abstract 2
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract 2
- 159000000007 calcium salts Chemical class 0.000 claims abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract 2
- 229910052751 metal Inorganic materials 0.000 claims abstract 2
- 239000002184 metal Substances 0.000 claims abstract 2
- 150000002739 metals Chemical class 0.000 claims abstract 2
- 239000006186 oral dosage form Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000007787 solid Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/24—Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/282—Porous sorbents
- B01J20/285—Porous sorbents based on polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Применение соли альгината в качестве сорбента липидов.2. Применение по п. 1, в котором соли альгината представлены солями двухвалентных металлов.3. Применение по п. 2, в котором соли альгината представлены солями кальция.4. Применение по любому из пп. 1-3, в котором гранулы соли альгината имеют размеры 0,1-2 мм.5. Применение по любому из пп. 1-3, характеризующееся тем, что гранулы получены методом ионотропного гелеобразования.6. Применение по любому из пп. 1-3, характеризующееся тем, что ионотропное гелеобразование проводят с помощью технологии вибрирующего сопла.7. Фармацевтическая композиция для снижения всасывания липидов в желудочно-кишечном тракте, характеризующаяся тем, что в качестве сорбента липидов содержит гранулы соли альгината в эффективном количестве и фармацевтически допустимые вспомогательные вещества.8. Фармацевтическая композиция по п. 7, характеризующаяся тем, что содержит гранулы альгината поперечно-сшитого ионами кальция.9. Лекарственный препарат для лечения ожирения, характеризующийся тем, что представляет собой твердую пероральную лекарственную форму с фармацевтической композицией по п. 7 или 8.1. The use of alginate salt as a lipid sorbent. 2. The use according to claim 1, wherein the alginate salts are salts of divalent metals. The use of claim 2, wherein the alginate salts are calcium salts. The use according to any one of paragraphs. 1-3, in which the granules of the alginate salt have a size of 0.1-2 mm. 5. The use according to any one of paragraphs. 1-3, characterized in that the granules are obtained by ionotropic gelation. 6. The use according to any one of paragraphs. 1-3, characterized in that the ionotropic gelation is carried out using the technology of a vibrating nozzle. 7. A pharmaceutical composition for reducing the absorption of lipids in the gastrointestinal tract, characterized in that the sorbent of lipids contains granules of alginate salt in an effective amount and pharmaceutically acceptable excipients. 8. A pharmaceutical composition according to claim 7, characterized in that it contains granules of alginate crosslinked by calcium ions. A medicament for the treatment of obesity, characterized in that it is a solid oral dosage form with a pharmaceutical composition according to claim 7 or 8.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014147869A RU2646788C2 (en) | 2014-11-27 | 2014-11-27 | Use of alginate salt as lipid sorbent, pharmaceutical composition and medicament for treatment of obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014147869A RU2646788C2 (en) | 2014-11-27 | 2014-11-27 | Use of alginate salt as lipid sorbent, pharmaceutical composition and medicament for treatment of obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014147869A true RU2014147869A (en) | 2016-06-20 |
| RU2646788C2 RU2646788C2 (en) | 2018-03-07 |
Family
ID=56131818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014147869A RU2646788C2 (en) | 2014-11-27 | 2014-11-27 | Use of alginate salt as lipid sorbent, pharmaceutical composition and medicament for treatment of obesity |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2646788C2 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9089152B2 (en) * | 2009-04-13 | 2015-07-28 | TEAGASC—Agriculture and Food Development Authority | Method of producing microbeads |
-
2014
- 2014-11-27 RU RU2014147869A patent/RU2646788C2/en active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2646788C2 (en) | 2018-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016034978A5 (en) | ||
| JP2014218522A5 (en) | ||
| WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| MX383665B (en) | COMPOSITIONS OF DONEPEZIL AND METHODS FOR TREATING ALZHEIMER'S DISEASE. | |
| EA201692392A1 (en) | NEW MEDICINE FORM OF MELOXYCAM | |
| EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
| EA201692111A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES | |
| PE20151746A1 (en) | BICYCLE COMPOUNDS | |
| MX389336B (en) | PHARMACEUTICAL FORMULATION. | |
| EA201690974A1 (en) | HYDROMORPHONE AND NALOXONE FOR THE TREATMENT OF PAIN AND OPIOID-INITIATED INTESTINAL DYSFUNCTION SYNDROME | |
| HK1247837A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| CY1119532T1 (en) | (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
| RU2016112257A (en) | COMPOSITION FOR THE TREATMENT OF HYPERTENSION AND / OR FIBROSIS | |
| EA201992382A2 (en) | ORAL TABLET PHARMACEUTICAL COMPOSITION FOR DOUBLE USE ON THE BASIS OF SULPHATE SALTS AND METHODS OF ITS APPLICATION | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| CY1119522T1 (en) | (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| RU2014147869A (en) | The use of alginate salt as a lipid sorbent, pharmaceutical composition and drug for the treatment of obesity | |
| RU2013127794A (en) | PHARMACEUTICAL COMBINATION AND COMPOSITION FOR TREATING OBESITY AND ITS APPLICATION | |
| RU2016127361A (en) | GASTRORETENTIVE PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION | |
| BR112015015938A2 (en) | use of phenylephrine and acetaminophen hydrochloride, drug, method of treatment of upper respiratory tract mucosal congestion in an adult human | |
| JP2017509683A5 (en) | ||
| WO2015166418A3 (en) | Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient | |
| IN2013MU03428A (en) |